acquired Actient Holdings, a private urology specialty therapeutics company, for $585 millionActient‚s products include Testopel, a long-acting implantable testosterone replacement therapy; Edex, a non-oral drug for erectile dysfunction; and Osbon ErecAid, ...
[Published Philadelphia Business Journal - Apr 29 2013]